CA2511881C - Compositions pharmaceutiques comprenant un sel de sodium de celecoxib a dissolution amelioree - Google Patents

Compositions pharmaceutiques comprenant un sel de sodium de celecoxib a dissolution amelioree Download PDF

Info

Publication number
CA2511881C
CA2511881C CA2511881A CA2511881A CA2511881C CA 2511881 C CA2511881 C CA 2511881C CA 2511881 A CA2511881 A CA 2511881A CA 2511881 A CA2511881 A CA 2511881A CA 2511881 C CA2511881 C CA 2511881C
Authority
CA
Canada
Prior art keywords
celecoxib
degrees
sodium salt
ray diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2511881A
Other languages
English (en)
Other versions
CA2511881A1 (fr
Inventor
Mark Tawa
Julius Remenar
Matthew Peterson
Orn Almarsson
Hector Guzman
Hongming Chen
Mark Oliveira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/019574 external-priority patent/WO2004000284A1/fr
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/fr
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/028982 external-priority patent/WO2004026235A2/fr
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/fr
Publication of CA2511881A1 publication Critical patent/CA2511881A1/fr
Application granted granted Critical
Publication of CA2511881C publication Critical patent/CA2511881C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes permettant de cribler des mélanges contenant un composant pharmaceutique et un excipient afin d'identifier les propriétés de la combinaison composant pharmaceutique/excipient retardatrice de la nucléation à l'état solide. L'invention concerne également l'augmentation de la solubilité, de la dissolution et de la biodisponibilité d'un médicament à faible solubilité dans des conditions de fluides gastriques par combinaison du médicament avec un agent retardateur de précipitation et d'un éventuel amplificateur.
CA2511881A 2002-12-30 2003-12-24 Compositions pharmaceutiques comprenant un sel de sodium de celecoxib a dissolution amelioree Expired - Fee Related CA2511881C (fr)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US43751602P 2002-12-30 2002-12-30
US60/437,516 2002-12-30
US44133503P 2003-01-21 2003-01-21
US60/441,335 2003-01-21
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US45660803P 2003-03-21 2003-03-21
US60/456,608 2003-03-21
US45950103P 2003-04-01 2003-04-01
US60/459,501 2003-04-01
USPCT/US03/19574 2003-06-20
PCT/US2003/019574 WO2004000284A1 (fr) 2002-06-21 2003-06-20 Compositions pharmaceutiques a dissolution amelioree
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/601,092 2003-06-20
US48671303P 2003-07-11 2003-07-11
US48706403P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
US60/486,713 2003-07-11
PCT/US2003/027772 WO2004078161A1 (fr) 2003-02-28 2003-09-04 Compositions co-cristallines pharmaceutiques de medicaments, notamment de carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophene, aspirine, flurbiprofene, phenytoine et ibuprofene
USPCT/US03/27772 2003-09-04
US10/660,202 2003-09-11
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
USPCT/US03/28982 2003-09-16
PCT/US2003/028982 WO2004026235A2 (fr) 2002-09-20 2003-09-16 Compositions pharmaceutiques presentant une dissolution amelioree
PCT/US2003/041273 WO2004061433A1 (fr) 2002-12-30 2003-12-24 Compositions pharmaceutiques a dissolution amelioree

Publications (2)

Publication Number Publication Date
CA2511881A1 CA2511881A1 (fr) 2004-07-22
CA2511881C true CA2511881C (fr) 2013-06-25

Family

ID=46124010

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2511881A Expired - Fee Related CA2511881C (fr) 2002-12-30 2003-12-24 Compositions pharmaceutiques comprenant un sel de sodium de celecoxib a dissolution amelioree

Country Status (4)

Country Link
EP (1) EP1579198A1 (fr)
JP (1) JP5021934B2 (fr)
AU (1) AU2003303591A1 (fr)
CA (1) CA2511881C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059605A1 (fr) * 2007-11-08 2009-05-14 University Of Copenhagen Tri de solides à petite échelle
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
WO2014043336A2 (fr) * 2012-09-13 2014-03-20 Cba Pharma, Inc. Formulations pharmaceutiques de tétrandrine et procédé associé

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216869C (zh) * 1999-12-08 2005-08-31 药品公司 赛利可喜的多态晶型
BR0107456A (pt) * 2000-01-07 2002-10-08 Transform Pharmaceuticals Inc Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
BR0312111A (pt) * 2002-06-26 2005-03-29 Pharmacia Corp Formulação estável, lìquida, parenteral de parecoxib
US20040092566A1 (en) * 2002-11-12 2004-05-13 Graneto Matthew J. Celecoxib prodrug

Also Published As

Publication number Publication date
JP2006517527A (ja) 2006-07-27
EP1579198A1 (fr) 2005-09-28
AU2003303591A1 (en) 2004-07-29
CA2511881A1 (fr) 2004-07-22
JP5021934B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
US8362062B2 (en) Pharmaceutical compositions with improved dissolution
EP1150959B1 (fr) Forme solide de celecoxib, presentant une biodisponibilite accrue
AU2002254609B2 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (COX-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
AU2002254609A1 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (COX-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
CZ20013210A3 (cs) Pevná forma celecoxibu mající zvýąenou biologickou dostupnost
NZ513963A (en) Valdecoxib compositions
WO2001041536A2 (fr) Celecoxib a l'etat solide ayant une biodisponibilite amelioree
US20060052432A1 (en) Pharmaceutical compositions with improved dissolution
WO2004061433A1 (fr) Compositions pharmaceutiques a dissolution amelioree
CA2511881C (fr) Compositions pharmaceutiques comprenant un sel de sodium de celecoxib a dissolution amelioree
EP2339328A2 (fr) Compositions pharmaceutiques cocrystallisees de celecoxib
US6864373B2 (en) Stable amorphous celecoxib composite and process therefor
KR20050016596A (ko) 용해성이 개선된 약학 조성물
ZA200307576B (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (Cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191224

MKLA Lapsed

Effective date: 20191224